Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 11/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29856005 | 0.87 | ABL1 (0.36) | HDAC1HDAC8HDAC6ABL1ADORA2A | |
| SCHEMBL20839182 | 0.87 | ABL1 (0.36) | HDAC1HDAC8HDAC6ABL1ADORA2A | |
| SCHEMBL19384230 | 0.83 | IRAK4 (0.35) | HDAC1HDAC8HDAC6ABL1GPBAR1 | |
| SCHEMBL29725001 | 0.83 | IRAK4 (0.35) | HDAC1HDAC8HDAC6ABL1GPBAR1 | |
| SCHEMBL20845417 | 0.83 | ABL1 (0.34) | ABL1GPBAR1 | |
| SCHEMBL22380822 | 0.80 | IDH1 (0.33) | ABL1 | |
| SCHEMBL19450112 | 0.79 | PAX8 (0.39) | HDAC1HDAC8HDAC6ABL1CACNA1G | |
| SCHEMBL20852928 | 0.79 | ABL1 (0.35) | ABL1 | |
| SCHEMBL20841415 | 0.77 | CYP17A1 (0.39) | ABL1 | |
| SCHEMBL22372368 | 0.77 | ABL1 (0.34) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3684763-B1 | PYRIMIDIN-4-CARBAMATE OR UREA DERIVATIVES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-11-17 | — | — | EP | disclosed |
| US-20200288711-A1 | Pyrimidin-4-Carbamate or Urea Derivatives As Herbicides | SYNGENTA PARTICIPATIONS AG (CH) | 2020-09-17 | — | — | US | disclosed |
| WO-2019057722-A1 | PYRIMIDIN-4-CARBAMATE OR UREA DERIVATIVES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200288711-A1 | Pyrimidin-4-Carbamate or Urea Derivatives As Herbicides | PLPBP, DDT, UMPS | HDAC1 2220/4885HDAC8 1683/4885HDAC6 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.